【摘要】 目的:探讨脊髓性肌萎缩症(SMA)患儿应用诺西那生钠注射液的临床疗效及安全性。方法:选取2022年1-6月于我院接受诺西那生钠鞘内注射治疗的SMA患儿26例,于治疗当天(T0)、第14天(T1)、第28天(T2)及第63天(T3)评估并比较Hammersmith扩展功能运动量表(HFMSE)、上肢模块修订版(RULM)、6分钟步行试验(6MWT)及不良反应发生情况。结果:与T0比较,T3时HFMSE评分升高[(20.69±14.64)分vs.(23.38±15.69)分, P<0.01]。与T0比较,T3时RULM评分升高[(18.27±10.15)分vs.(19.88±10.21)分,P<0.05]。结论:SMA患儿应用诺西那生钠注射液治疗后,HFMSE和RULM评分显著提高,近端肢体运动功能明显改善,且无明显不良反应发生。更多还原

【Abstract】 Objective:spinal To probe（SMA）.our into the clinical efficacy From and 2022 safety to of Jun.norcyclosporine2022,sodium children injection SMA in who the treatment received of intrathecal scores,children injection Revised with of Upper day Methods:muscular nusinersen atrophy sodium Jan.26Motor drug with in hospital and were6-Minute enrolled.Walk Hammersmith Test Functional and Scale reactions（T2）,Expanded were（HFMSE）evaluated Limb Module treatment（RULM）,（6MWT）adverse of and of compared treatment on（T3）.the of Results:14^th HFMSE at28^th63^rd（T0）,the T0,scores day of scores was treatment at（T1）,was the higher day treatment and the day vs.（23.38±15.69）P<0.01).Conclusion:Compared T0,with RULM T3（（20.69±14.64）points points,Compared The with vs.（19.88±10.21）P<0.05）.with T3motor higher function(（18.27±10.15）proximal points points,treatment HFMSE and children RULM with scores SMA.and of limb are significantly improved after nocinazone sodium injection in更多还原